{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:14:40Z","timestamp":1780514080535,"version":"3.54.1"},"reference-count":35,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,2,26]],"date-time":"2013-02-26T00:00:00Z","timestamp":1361836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2013,2,26]],"date-time":"2013-02-26T00:00:00Z","timestamp":1361836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"crossref","award":["CZ.1\u00b705\/1\u00b71\u00b700\/02\u00b70068"],"award-info":[{"award-number":["CZ.1\u00b705\/1\u00b71\u00b700\/02\u00b70068"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]},{"name":"\u2018CEITEC - Central European Institute of Technology\u2019","award":["P206\/10\/0057"],"award-info":[{"award-number":["P206\/10\/0057"]}]},{"name":"\u2018CEITEC - Central European Institute of Technology\u2019","award":["CZ.1\u00b705\/1\u00b71\u00b700\/02\u00b70068"],"award-info":[{"award-number":["CZ.1\u00b705\/1\u00b71\u00b700\/02\u00b70068"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1111\/jcpt.12042","type":"journal-article","created":{"date-parts":[[2013,2,26]],"date-time":"2013-02-26T08:34:17Z","timestamp":1361867657000},"page":"294-300","source":"Crossref","is-referenced-by-count":10,"title":["Dynamics and persistence of CYP2D6 inhibition by paroxetine"],"prefix":"10.1155","volume":"38","author":[{"given":"J.","family":"Ju\u0159ica","sequence":"first","affiliation":[{"name":"Department of Pharmacology; Faculty of Medicine; Central European Institute of Technology (CEITEC); Masaryk University; Brno Czech Republic"},{"name":"Experimental and Applied Neuropsychopharmacology Research Group; Central European Institute of Technology (CEITEC); Masaryk University; Brno Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"\u017dourkov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Psychiatry; Central European Institute of Technology (CEITEC); Masaryk University; Brno Czech Republic"},{"name":"Behavioral and Social Neuroscience Research Group; Central European Institute of Technology (CEITEC); Masaryk University; Brno Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,2,26]]},"reference":[{"key":"10.1111\/jcpt.12042-BIB0001|jcpt12042-cit-0001","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0278-5846(02)00338-X","article-title":"Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review","volume":"27","author":"Vaswani","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1111\/jcpt.12042-BIB0002|jcpt12042-cit-0002","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1124\/dmd.31.3.289","article-title":"Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine","volume":"31","author":"Bertelsen","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/jcpt.12042-BIB0003|jcpt12042-cit-0003","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/clpt.1993.43","article-title":"Inhibition by fluoxetine of cytochrome-P450 2d6 activity","volume":"53","author":"Otton","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12042-BIB0004|jcpt12042-cit-0004","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/0-387-27447-2_7","volume-title":"Cytochrome P450: structure, mechanism, and biochemistry","author":"Correia","year":"2005","edition":"3"},{"key":"10.1111\/jcpt.12042-BIB0005|jcpt12042-cit-0005","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1146\/annurev.pharmtox.41.1.535","article-title":"Interindividual variability in inhibition and induction of cytochrome P450 enzymes","volume":"41","author":"Lin","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1111\/jcpt.12042-BIB0006|jcpt12042-cit-0006","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00204-008-0332-8","article-title":"Inhibition and induction of human cytochrome P450 enzymes: current status","volume":"82","author":"Pelkonen","year":"2008","journal-title":"Arch Toxicol"},{"key":"10.1111\/jcpt.12042-BIB0007|jcpt12042-cit-0007","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2125.1995.tb05793.x","article-title":"The effects of selective serotonin reuptake inhibitors and their metabolites on S-Mephenytoin 4\u2032-Hydroxylase activity in human liver-microsomes","volume":"40","author":"Kobayashi","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jcpt.12042-BIB0008|jcpt12042-cit-0008","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/01.fpc.0000239974.69464.f2","article-title":"CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure","volume":"17","author":"Sistonen","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1111\/jcpt.12042-BIB0009|jcpt12042-cit-0009","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.bbagen.2006.09.019","article-title":"Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes","volume":"1770","author":"Kirchheiner","year":"2007","journal-title":"Biochim Biophys Acta, Gen Subj"},{"key":"10.1111\/jcpt.12042-BIB0010|jcpt12042-cit-0010","unstructured":"WHO International classification of diseases X; classification of mental and behavioural disorders WHO http:\/\/apps.who.int\/classifications\/icd10\/browse\/2010\/en"},{"key":"10.1111\/jcpt.12042-BIB0011|jcpt12042-cit-0011","first-page":"132","article-title":"HPLC determination of dextromethorphan and its metabolites in urine","volume":"94","author":"Zimova","year":"2000","journal-title":"Chem Listy"},{"key":"10.1111\/jcpt.12042-BIB0012|jcpt12042-cit-0012","first-page":"284","article-title":"Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences","volume":"60","author":"Sachse","year":"1997","journal-title":"Am J Hum Genet"},{"key":"10.1111\/jcpt.12042-BIB0013|jcpt12042-cit-0013","first-page":"21","article-title":"Rating depressive patients","volume":"41","author":"Hamilton","year":"1980","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/jcpt.12042-BIB0014|jcpt12042-cit-0014","first-page":"79","article-title":"Diagnosis and rating of anxiety","volume":"3","author":"Hamilton","year":"1969","journal-title":"Br J Psychiatry"},{"key":"10.1111\/jcpt.12042-BIB0015|jcpt12042-cit-0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The Uku side-effect rating-scale - a new comprehensive rating-scale for psychotropic-drugs and a cross-sectional study of side-effects in neuroleptic-treated patients - preface","volume":"76","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr Scand"},{"key":"10.1111\/jcpt.12042-BIB0016|jcpt12042-cit-0016","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/BF03016672","article-title":"Serotonin toxicity caused by an interaction between fentanyl and paroxetine","volume":"55","author":"Rang","year":"2008","journal-title":"Can J Anaesth -Journal Canadien D Anesthesie"},{"key":"10.1111\/jcpt.12042-BIB0017|jcpt12042-cit-0017","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1023\/A:1008629608556","article-title":"Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir","volume":"19","author":"Hoetelmans","year":"1997","journal-title":"Pharm World Sci"},{"key":"10.1111\/jcpt.12042-BIB0018|jcpt12042-cit-0018","first-page":"305","article-title":"Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia","volume":"18","author":"Silver","year":"2003","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1111\/jcpt.12042-BIB0019|jcpt12042-cit-0019","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00004850-199805000-00009","article-title":"Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia","volume":"13","author":"Spina","year":"1998","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1111\/jcpt.12042-BIB0020|jcpt12042-cit-0020","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/00926230701385589","article-title":"Links among paroxetine-induced sexual dysfunctions, gender, and CYP2D6 activity","volume":"33","author":"Zourkova","year":"2007","journal-title":"J Sex Marital Ther"},{"key":"10.1111\/jcpt.12042-BIB0021|jcpt12042-cit-0021","first-page":"103","article-title":"Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects","volume":"22","author":"Zourkova","year":"2003","journal-title":"Gen Physiol Biophys"},{"key":"10.1111\/jcpt.12042-BIB0022|jcpt12042-cit-0022","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1016\/S0924-977X(03)91857-8","article-title":"Phenotype dynamics and its clinical correlates in patients treated by paroxetine","volume":"13","author":"Zourkova","year":"2003","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1111\/jcpt.12042-BIB0023|jcpt12042-cit-0023","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2125.2006.02629.x","article-title":"Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling","volume":"61","author":"Feng","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jcpt.12042-BIB0024|jcpt12042-cit-0024","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/clpt.1992.23","article-title":"The relationship between paroxetine and the sparteine oxidation polymorphism","volume":"51","author":"Sindrup","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12042-BIB0025|jcpt12042-cit-0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0163-7258(99)00048-0","article-title":"Pharmacokinetics of selective serotonin reuptake inhibitors","volume":"85","author":"Hiemke","year":"2000","journal-title":"Pharmacol Ther"},{"key":"10.1111\/jcpt.12042-BIB0026|jcpt12042-cit-0026","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00004714-200204000-00010","article-title":"Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers","volume":"22","author":"Liston","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"10.1111\/jcpt.12042-BIB0027|jcpt12042-cit-0027","doi-asserted-by":"crossref","first-page":"S744","DOI":"10.1111\/j.1365-2125.2004.02282.x","article-title":"The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes","volume":"58","author":"Crewe","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jcpt.12042-BIB0028|jcpt12042-cit-0028","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/0003088-200948010-00005","article-title":"Steady-state concentrations of mirtazapine, N-Desmethylmirtazapine, 8-Hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour","volume":"48","author":"Lind","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/jcpt.12042-BIB0029|jcpt12042-cit-0029","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s002280050408","article-title":"Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin","volume":"53","author":"Muck","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/jcpt.12042-BIB0030|jcpt12042-cit-0030","first-page":"409","article-title":"Lack of drug-drug interaction between cerivastatin and nifedipine","volume":"36","author":"Sachse","year":"1998","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12042-BIB0031|jcpt12042-cit-0031","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s002280000218","article-title":"In-vivo indices of CYP2D6 activity: comparison of dextromethorphan metabolic ratios in 4-h urine and 3-h plasma","volume":"56","author":"Chladek","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/jcpt.12042-BIB0032|jcpt12042-cit-0032","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2133\/dmpk.25.243","article-title":"Estimation of the interindividual variability of cytochrome 2d6 activity from urinary metabolic ratios in the literature","volume":"25","author":"Ito","year":"2010","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1111\/jcpt.12042-BIB0033|jcpt12042-cit-0033","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.pain.2009.03.023","article-title":"Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation?","volume":"144","author":"Lotsch","year":"2009","journal-title":"Pain"},{"key":"10.1111\/jcpt.12042-BIB0034|jcpt12042-cit-0034","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00210-003-0832-2","article-title":"Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry","volume":"369","author":"Zanger","year":"2004","journal-title":"N-S Arch Pharmacol"},{"key":"10.1111\/jcpt.12042-BIB0035|jcpt12042-cit-0035","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1046\/j.1472-8206.2003.00193.x","article-title":"Metabolic drug interactions with new psychotropic agents","volume":"17","author":"Spina","year":"2003","journal-title":"Fundam Clin Pharmacol"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12042","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12042","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12042\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:04:54Z","timestamp":1671818694000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,26]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12042","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2,26]]}}}